Result of General Meeting

30 April 2015

Sphere Medical Holding plc

Result of General Meeting

Cambridge, UK, 30 April 2015: Sphere Medical Holding plc (AIM: SPHR.L), ("Sphere" or "Sphere Medical" or the "Company") a leading provider of innovative monitoring and diagnostic devices for the critical care setting, announces that at the General Meeting held earlier today, all the resolutions proposed were unanimously passed.

The full text of the resolutions can be found in the Notice of the General Meeting set out in the Circular published by the Company on 13 April 2015 and on the Company's website www.spheremedical.com.

Application has been made to AIM, a market of the London Stock Exchange plc, for the admission of 82,352,582 New Ordinary Shares. It is expected that Admission will become effective at 8.00 a.m. on 1 May 2015. Following Admission, the Company will have 141,757,872 Ordinary Shares in issue.

Unless otherwise defined, terms in this announcement shall have the same meanings as those defined in the shareholder circular dated 13 April 2015.

For further information, please contact:

Notes for Editors

About Sphere Medical (AIM: SPHR.L)

Sphere Medical is a medical device company developing and commercialising a range of innovative monitoring and diagnostic devices designed to significantly improve patient care.

Sphere Medical's vision is to become a leading solution provider to the critical care market offering innovative, near real time, point of care diagnostic and monitoring products to enable closer control of therapeutic response and improve patient outcomes and reduce the overall cost of care.

The Company's strategy is focused on developing the Proxima (CE marked device) platform for measuring blood gases, electrolytes and metabolites. The Company is already marketing its Proxima product directly to the critical care market, which includes the ICU and OR, with a dedicated field sales force in the UK. Sphere has plans to follow in Germany and Benelux via a direct sales force in Europe and proposes to work with partners for worldwide distribution.

Proxima delivers near real time analysis of blood gases and electrolytes metabolites, at the patient's bedside. Proxima can be used on patients across a wide therapeutic range, enabling faster clinical decision making and improved patient outcomes, whilst potentially reducing costs for healthcare payers.

Sphere Medical entered into a collaboration agreement with Ortho-Clinical Diagnostics, Inc. in 2013 for the development of Proxima and enhancement of Sphere's operational and production capabilities.

Sphere Medical has a number of partnerships with industry leading medical device companies and has received a strategic investment from Ortho-Clinical Diagnostics (now part of Carlyle Group).

For further information, please visit www.spheremedical.com